Kadmon

Kadmon Corporation, a biopharmaceutical company, offers products and services for the treatment and management of hepatitis C. Its products include Ribasphere RibaPak (ribavirin, USP) tablets, which help to reduce pill burden while providing patients with treatment that is biologically equivalent to other ribavirin medications; INFERGEN (interferon alfacon-1) to treat chronic hepatitis C in patients 18 years of age or older with compensated liver disease; Ribasphere (ribavirin, USP) tablets and capsules, which are antiviral medications for use in combination with other drugs for the treatment of chronic hepatitis C; and KD020, a reversible tyrosine kinase inhibitor that targets EGFR, HER2, VEGFR 2/3, and Src in autosomal dominant polycystic kidney disease (PKD). Show more